Search

Home > GRACEcast Lung Cancer Video > Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
Podcast: GRACEcast Lung Cancer Video
Episode:

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
Category: Science & Medicine
Duration: 00:07:28
Publish Date: 2014-07-17 14:00:00
Description:

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Total Play: 0